All Outputs (5)

Lysosomal positioning regulates Rab10 phosphorylation at LRRK2 + lysosomes (2022)
Journal Article
Kluss, J. H., Beilina, A., Williamson, C. D., Lewis, P. A., Cookson, M. R., & Bonet-Ponce, L. (2022). Lysosomal positioning regulates Rab10 phosphorylation at LRRK2 + lysosomes. Proceedings of the National Academy of Sciences, 119(43), https://doi.org/10.1073/pnas.2205492119

Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins (2022)
Journal Article
Cogo, S., Tomkins, J., Vavouraki, N., Giusti, V., Forcellato, F., Franchin, C., Tessari, I., Arrigoni, G., Cendron, L., Manzoni, C., Civiero, L., Lewis, P., & Greggio, E. (2022). Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins. Neurobiology of Disease, 174, https://doi.org/10.1016/j.nbd.2022.105858

Mutations in SPG11, encoding spatacsin, constitute the major cause of autosomal recessive Hereditary Spastic Paraplegia (HSP) with thinning of the corpus callosum. Previous studies showed that spatacsin orchestrates cellular traffic events through th... Read More about Cytosolic sequestration of spatacsin by Protein Kinase A and 14-3-3 proteins.

Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at 16q11.2 and MAPT H1 loci (2022)
Journal Article
Soutar, M. P. M., Melandri, D., O’Callaghan, B., Annuario, E., Monaghan, A. E., Welsh, N. J., D’Sa, K., Guelfi, S., Zhang, D., Pittman, A., Trabzuni, D., Verboven, A. H. A., Pan, K. S., Kia, D. A., Bictash, M., Gandhi, S., Houlden, H., Cookson, M. R., Kasri, N. N., Wood, N. W., …Plun-Favreau, H. (2022). Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at 16q11.2 and MAPT H1 loci. Brain, 145(12), 4349-4367. https://doi.org/10.1093/brain/awac325

Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line (2022)
Journal Article
Ruz, C., Alcantud, J., Vives, F., Arrebola, F., Hardy, J., Lewis, P., Manzoni, C., & Duran, R. (2022). Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line. International Journal of Molecular Sciences, 23(13), https://doi.org/10.3390/ijms23136935

A step forward for LRRK2 inhibitors in Parkinson's disease (2022)
Journal Article
Lewis, P. (2022). A step forward for LRRK2 inhibitors in Parkinson's disease. Science Translational Medicine, 14(648), https://doi.org/10.1126/scitranslmed.abq7374

A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.